CL2013003645A1 -
Monoclonal anti-ax1 antibody (tam subfamily of tyrosine kinase receptors); fragment of said antibody; vector and cell that comprise it; pharmaceutical composition comprising it; Use to treat cancer.
- Google Patents
Monoclonal anti-ax1 antibody (tam subfamily of tyrosine kinase receptors); fragment of said antibody; vector and cell that comprise it; pharmaceutical composition comprising it; Use to treat cancer.
Inst Regional Du Cancer De Montpellier Val D Aurelle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=65657120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003645(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Oribase Pharma, Univ De Montpellier 1, Inst Regional Du Cancer De Montpellier Val D AurellefiledCriticalInst Nat Sante Rech Med
Publication of CL2013003645A1publicationCriticalpatent/CL2013003645A1/en
CL2013003645A2011-06-222013-12-19
Monoclonal anti-ax1 antibody (tam subfamily of tyrosine kinase receptors); fragment of said antibody; vector and cell that comprise it; pharmaceutical composition comprising it; Use to treat cancer.
CL2013003645A1
(en)
Monoclonal anti-ax1 antibody (tam subfamily of tyrosine kinase receptors); fragment of said antibody; vector and cell that comprise it; pharmaceutical composition comprising it; Use to treat cancer.
Isolated antibody or fragment that binds to an inactive state of a her receptor; pharmaceutical composition comprising it; use of the antibody to treat cancer
Antibody that specifically binds to the fibroblastic activation protein (fap); polynucleotide that encodes it; vector; host cell; Method of production; pharmaceutical formulation that includes it; and its use to treat cancer.
Bispecific antibody that specifically binds to human erbb-3 and human c-met proteins; nucleic acid encoding it; pharmaceutical composition that includes it; and its use to treat cancer
Compounds derived from imidazotriazincarbonitriles, protein kinase inhibitors; pharmaceutical composition that includes them; and its use to treat cancer, psoriasis and rheumatoid arthritis.
Isolated monoclonal antibody that binds to an epitope of the human tissue factor pathway inhibitor; nucleic acid molecule that encodes it; pharmaceutical composition that includes it; and its use to treat deficiencies or genetic or acquired defects in coagulation.
Antibodies from a single dab variable domain that bind to human cd40; nucleic acid encoding said antibody; vector and host cell that comprise it; pharmaceutical composition; use of said antibodies to treat immune disease.
Binding molecule that binds to cd134 (ox40); nucleic acid molecule that encodes it; vector; host cell; Preparation process; pharmaceutical composition that includes it; and its use to treat cancer.
Compounds derived from benzothienyl-pyrrolotriazine, such as protein tyrosine kinase inhibitors; preparation process of said compounds; pharmaceutical composition that includes them; and its use for the treatment and / or prevention of cancer and tumor diseases.
ANTI-RECEIVER ANTIBODY OF INSULINAL GROWTH FACTOR I (IGF-IR); POLINUCLEOTIDE THAT CODIFIES IT; METHOD OF PRODUCTION; COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT CANCER.
polypeptide production methods, multispecific binder production, multispecific binder selection, bispecific antibody selection and combination determination, bispecific antibody, pharmaceutical formulation and use of bispecific antibody
Polypeptide derived from il-2 with agonist activity; fusion protein that comprises it; pharmaceutical composition that includes it; and its use to treat cancer and chronic infectious diseases.
Composition comprising bispecific cd19xcd3 antibody to treat tumor mass of lymph node tissue and / or extranodal lymphoma caused by diffuse large cell lymphoma b (lbdcg); pharmaceutical kit; Use of the composition.